The clinical implications of the Prostate Cancer Prevention Trial
Open Access
- 27 October 2003
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 92 (7) , 667-671
- https://doi.org/10.1046/j.1464-410x.2003.04486.x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- The Influence of Finasteride on the Development of Prostate CancerNew England Journal of Medicine, 2003
- Associations of Serum Testosterone with Microvessel Density, Androgen Receptor Density and Androgen Receptor Gene polymorphism In prostate cancerJournal of Urology, 2003
- Pathologic features of prostate cancer found at population-based screening with a four-year interval.JNCI Journal of the National Cancer Institute, 2001
- IS LOW SERUM FREE TESTOSTERONE A MARKER FOR HIGH GRADE PROSTATE CANCER?Journal of Urology, 2000
- Primary treatment choices for men with clinically localized prostate carcinoma detected by screeningCancer, 2000
- The early detection of prostate carcinoma with prostate specific antigenCancer, 1997
- Population-based study of long-term survival in patients with clinically localised prostate cancerThe Lancet, 1997
- Design of the Prostate Cancer Prevention Trial (PCPT)Controlled Clinical Trials, 1995
- Prognostic Factors in Survival Free of Progression After Androgen Deprivation Therapy for Treatment of Prostate CancerJournal of Urology, 1989
- Prostatic cancer.XI. Early prostatic cancer diagnosed by arbitrary open perineal biopsy among 300 unselected patientsCancer, 1954